🇺🇸 LY2157299 in United States
4 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 4
Most-reported reactions
- Lung Infection — 2 reports (50%)
- Pulmonary Toxicity — 1 report (25%)
- Pyrexia — 1 report (25%)
Frequently asked questions
Is LY2157299 approved in United States?
LY2157299 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for LY2157299 in United States?
Eli Lilly and Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.